Despite naysayers and prevailing attitudes echoing into the present day, it’s clear today that psychedelic medicine at the very least carries potential in treating mental health conditions and symptoms that have otherwise been difficult to treat or entirely resistant to treatment.

The model for legal psychedelic therapy, and most research looking at the efficacy of psychedelics for mental health treatments, is generally understood through psychedelic therapy centers. For states that have legalized psychedelic substances like psilocybin, or any number of ketamine clinics already operating in the U.S., this typically involves a combination of talk therapy, a controlled psychedelic dose, and supervision/guidance from a licensed professional.

But what about psychedelic retreats? These tailor-made psychedelic getaways typically take place in countries where psychedelic substances are allowed, similarly helping patients seeking symptom relief, or often a general mental reset, in a luxurious setting. 

Now, the public psychedelics practitioner training program F.I.V.E. has announced plans to collaborate with Tandava Retreats and University College London (UCL) on the first-ever EEG brain imaging study of 5-MeO-DMT among retreat center participants, Benzinga reports. 

Study collaborators are generally looking to uncover more information on 5-MeO-DMT’s mechanism of action and specifically within naturalistic settings over medical/clinical settings, along with how retreat participants could be better served as they use the substance in this setting.

The study’s principal investigator Jeremy Skipper said it’s important to look at the actual contexts these psychedelics are used in order to best understand the effects of such substances. 

“We hope to contribute not only to a better scientific understanding of how 5-MeO-DMT works in the brain, but also to enabling individualized approaches that maximize the efficacy of 5-MeO-DMT therapies and retreats,” Skipper told Benzinga.

Tandava CEO Joel Brierre, who is also the CEO of F.I.V.E., will coordinate the study along with F.I.V.E. President Victoria Wueschner. It will gather both qualitative and quantitative data from Tandava participants, assessing changes in well-being, beliefs, and personality. The study will use spontaneous neural imagery electroencephalography (EEG) on participants both before and during the psychoactive experience.

“These retreats allow you to explore the deepest realms of your innermost being, address behavioral habits that no longer serve you, and give you the freedom of life that you seek,” the Tandava website states. “We believe that no one should be a victim of their own mental patterning.”

Tandava is located in Tepoztlan, Mexico, and has the amenities anyone might expect on a tropical vacation: a hot jacuzzi, sauna, communal spaces, plenty of food and drink and private rooms for all visitors. With practitioners and integration specialists with varying backgrounds, Tandava offers a number of options, including a “transcultural” framework, an Indigenous/Shamanic approach, even a journey grounded by yoga. 

The site also mentions that each Tandava guide has been on their own psychedelic journey. 

Research has already affirmed that 5-MeO-DMT used in a naturalistic group setting can improve depression and anxiety, though of course there’s still a lot of catching up to do to fully understand its impacts, and the impacts of other psychedelic substances. The compound generally comes from the Sonoran Desert toad, Bufo alvarius, though Tandava Retreats uses synthetic 5-MeO-DMT to support species conservation and sourcing sustainability.

“We have found the experience of synthetic 5-MeO-DMT to be identical in nature to the toad secretion, which is important to note during the rise in popularity of this medicine,” Brierre told Benzinga. “Not only is synthetic safer and more effective to use with participants, but it has the repeatable consistency and precision dosage needed for proper research to be done.”

The study will cost about $108,437, though a U.K.-based charity has already donated $40,898 to the cause. Tandava will also match any funds raised and will donate retreat and integration costs for 15 of the 30 participants. There is also a crowdfund available for those interested in supporting the study.

The post UCL To Lead First-Ever Brain Imaging Study Among Psychedelic Retreat Participants appeared first on High Times.

The post UCL To Lead First-Ever Brain Imaging Study Among Psychedelic Retreat Participants appeared first on Paradise Found.

New research once again destroys the lazy stoner stereotype, or the cannabis amotivational syndrome theory, instead showing both teen and adult cannabis consumers are “no less likely” to be motivated, nor are they less likely to show interest in rewards.

”Cannabis amotivational syndrome” is a hypothesis tossed around from commentators in the media for years that suggests regular cannabis use can lead to apathy, or less motivation, and anhedonia, or loss of interest in pleasure from rewards.

These supposed impacts on motivation are part of the hysteria surrounding teen use of cannabis while in developmental years. NORML Deputy Director Paul Armentano wrote for High Times about “the media’s absurd hysteria about teens and pot” adding that claims such as amotivational syndrome are often invented or grossly exaggerated.

But this new study examined both apathy and anhedonia levels, measured against controls to determine if stoners are truly less motivated—in the way they are often portrayed in the media.

The study was published August 24 in the International Journal of Neuropsychopharmacology.

A team led by scientists at University College London (UCL), the University of Cambridge, and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London examined whether cannabis users show higher levels of apathy and anhedonia versus controls and whether they were less willing to exert physical effort to receive a reward.

The research was part of the CannTEEN study, which is also examining other factors involving teen cannabis use. For the study, 274 adults and teens were chosen if they had smoked or consumed weed at least weekly.

“Our results suggest that cannabis use at a frequency of three to four days per week is not associated with apathy, effort-based decision-making for reward, reward wanting, or reward liking in adults or adolescents,” the researchers concluded, however finding lower anhedonia in users, but with a “small effect size.”

Martine Skumlien, a PhD candidate in the Department of Psychiatry at the University of Cambridge, immediately noted the unfounded claims of the way cannabis is portrayed in the media.

“We were surprised to see that there was really very little difference between cannabis users and non-users when it came to lack of motivation or lack of enjoyment, even among those who used cannabis every day,” Skumlien said. “This is contrary to the stereotypical portrayal we see on TV and in movies.”

“There’s been a lot of concern that cannabis use in adolescence might lead to worse outcomes than cannabis use during adulthood,” Dr Will Lawn of the Institute of Psychiatry, Psychology and Neuroscience at King’s College London said. “But our study, one of the first to directly compare adolescents and adults who use cannabis, suggests that adolescents are no more vulnerable than adults to the harmful effects of cannabis on motivation, the experience of pleasure, or the brain’s response to reward.”

“In fact, it seems cannabis may have no link—-or at most only weak associations—with these outcomes in general. However, we need studies that look for these associations over a long period of time to confirm these findings.”

Over half of participants in the study carried out several tasks, with one assessing physical effort. Participants were given the option to perform button-presses in order to win points, which were later exchanged for chocolates or sweets. There were three difficulty levels and three reward levels, as more difficult trials required faster button pressing. For each test, the participant could choose to accept or reject the offer and points were only given if the test was accepted and completed.

A second task measured how much pleasure they received from rewards. The researchers found “no difference between users and non-users or between age groups on either the physical effort task or the real reward pleasure task, confirming evidence from other studies that found no, or very little, difference.”

Other recent studies also shred the cannabis amotivational syndrome theory.

A previous study, “Effort-related decision making and cannabis use among college students,” published January 27 in Experimental and Clinical Psychopharmacology, also disputes the cannabis-induced amotivational syndrome theory, finding no evidence to support it.

The post Teen and Adult Smokers ‘No Less Likely to be Motivated’ Study Shows appeared first on High Times.

The post Teen and Adult Smokers ‘No Less Likely to be Motivated’ Study Shows appeared first on Paradise Found.